Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

J Surg Oncol. 2009 Sep 15;100(4):331-4. doi: 10.1002/jso.21321.

Abstract

Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Ascites / etiology
  • Ascites / pathology
  • Ascites / therapy*
  • Chemotherapy, Cancer, Regional Perfusion*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Hyperthermia, Induced
  • Laparoscopy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neoplasms / surgery*
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Doxorubicin
  • Cisplatin